Piper Affirms Inovio Pharma (INO) at 'Overweight' Amid Increasingly Visible Clinical Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/24/2024
- Wall Street closes higher as investors digest earnings, megacap outlook
- Tesla touts acceleration of new models, but Q1 results fall short of estimates
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises as dollar slips, focus shifts to economic data
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Seagate Technology (STX) Enters $600M Asset Purchase Agreement with Avago
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- Wolfe Research Downgrades Warner Brothers Discovery (WBD) to Underperform, 'out of concern that an incipient advertising downturn put guidance at risk'
- Wall Street closes higher as investors digest earnings, megacap outlook
- After-hours movers: Tesla, Texas Instruments, Seagate, Visa and more
- Midday movers: PepsiCo, JetBlue fall; GM, Danaher and UPS rise
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
Inovio Pharmaceuticals Reports 2016 Second Quarter Financial Results
August 8, 2016 8:00 AM EDTPLYMOUTH MEETING, Pa., Aug. 08, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today reported financial results for the quarter ended June 30, 2016. The following financial results provide a year-over-year comparison of the second quarter in 2016 and 2015. Total revenue was $6.2 million compared to $5.3 million. Total operating expenses were $24.4 million compared to $20.4 million. The net loss attributable to common stockholders was $18.7 million, or $0.26 per share, compared to $6.2 million, or $0.09 per share.
Revenue
The increase in revenue was primarily due to an increase in development payments from our DARPA Ebola... More
Inovio Pharmaceuticals Appoints Dr. Ami Shah Brown As Vice President Regulatory Affairs
August 4, 2016 8:02 AM EDTPLYMOUTH MEETING, Pa., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ: INO) today announced the appointment of Dr. Ami Shah Brown as Vice President Regulatory Affairs. Dr. Brown, who joined Inovio in 2011 as Senior Director of Regulatory Affairs, will be responsible for developing and implementing Inovios regulatory strategies, including leadership over regulatory submissions, regulatory compliance, advertising and promotion review, and registrations to support Inovios product pipeline. Â Â
Dr. J. Joseph Kim, Inovios President & CEO, said, Ami has shown technical excellence and leadership in successfully moving our DNA-based... More
